Routine Blood Tests Do Not Predict Survival in Patients with Glioblastoma-Multivariable Analysis of 497 Patients.

[1]  Jing Xu,et al.  Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines , 2018, Journal of Extracellular Vesicles.

[2]  X. Breakefield,et al.  Multidimensional communication in the microenvirons of glioblastoma , 2018, Nature Reviews Neurology.

[3]  Jennifer C. Jones,et al.  Obstacles and opportunities in the functional analysis of extracellular vesicle RNA – an ISEV position paper , 2017, Journal of extracellular vesicles.

[4]  Alissa M. Weaver,et al.  Extracellular Vesicles: Unique Intercellular Delivery Vehicles. , 2017, Trends in cell biology.

[5]  Mark Lee,et al.  Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection , 2017, Cell.

[6]  K. E. Visser,et al.  Neutrophils in cancer: neutral no more , 2016, Nature Reviews Cancer.

[7]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[8]  X. Breakefield,et al.  Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake , 2016, Cellular and Molecular Neurobiology.

[9]  Qingchang Li,et al.  Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma , 2015, BMC Cancer.

[10]  A. Wu,et al.  The prognostic role of preoperative serum albumin levels in glioblastoma patients , 2015, BMC Cancer.

[11]  T. Luider,et al.  Circulating glioma biomarkers. , 2014, Neuro-oncology.

[12]  K. Pantel,et al.  Challenges in circulating tumour cell research , 2014, Nature Reviews Cancer.

[13]  D. Schadendorf,et al.  Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma , 2014, Nature.

[14]  W. Mason,et al.  Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression , 2014, Journal of Neuro-Oncology.

[15]  G. Fuller,et al.  Neutrophils Promote the Malignant Glioma Phenotype through S100A4 , 2013, Clinical Cancer Research.

[16]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[17]  S. Grossman,et al.  The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme , 2013, Journal of Neuro-Oncology.

[18]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[19]  A. Fiorentino,et al.  Elderly Patients Affected by Glioblastoma Treated With Radiotherapy: The Role of Serum Hemoglobin Level , 2012, The International journal of neuroscience.

[20]  Ishminder K. Kooner,et al.  Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival , 2012, Journal of Cancer Research and Clinical Oncology.

[21]  A. Vinciguerra,et al.  Prognostic impact of hemoglobin level and other factors in patients with high-grade gliomas treated with postoperative radiochemotherapy and sequential chemotherapy based on temozolomide , 2011, Strahlentherapie und Onkologie.

[22]  W. Wilson,et al.  Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.

[23]  V. Vila,et al.  Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma , 2011, Journal of Neuro-Oncology.

[24]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[25]  Johan Skog,et al.  Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers , 2008, Nature Cell Biology.

[26]  F. Lohr,et al.  Preoperative thrombocytosis predicts poor survival in patients with glioblastoma. , 2007, Neuro-oncology.

[27]  S. Blond,et al.  Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients , 2007, Acta Neurochirurgica.

[28]  Peter Vaupel,et al.  The role of hypoxia-induced factors in tumor progression. , 2004, The oncologist.

[29]  J. Knisely,et al.  Is There an Optimal Hemoglobin Level for Patients with Glioblastoma Multiforme? , 2004, Cancer journal.

[30]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[31]  S. Nemecek,et al.  Prognostic Impact of Hemoglobin Level Prior to Radiotherapy on Survival in Patients with Glioblastoma , 2003, Strahlentherapie und Onkologie.

[32]  Andreas Dietz,et al.  Predictive Value of the Tumor Oxygenation by Means of pO2 Histography in Patients with Advanced Head and Neck Cancer , 2001, Strahlentherapie und Onkologie.

[33]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[34]  M. Dewhirst,et al.  Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[35]  W. Liles,et al.  Glucocorticoids inhibit apoptosis of human neutrophils. , 1995, Blood.

[36]  W. Duncan,et al.  The influence of hemoglobin level on the regression and long term local control of transitional cell carcinoma of the bladder following photon irradiation. , 1986, International journal of radiation oncology, biology, physics.

[37]  T. Strojnik,et al.  Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma. , 2014, Anticancer research.

[38]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.

[39]  Elizabeth Eisenhauer,et al.  Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. , 2008, The Lancet. Oncology.

[40]  A. Egberts,et al.  Linking laboratory and medication data: new opportunities for pharmacoepidemiological research , 2007, Clinical chemistry and laboratory medicine.

[41]  W. Sauerbrei,et al.  Multivariate Analysis of Prognostic Factors in Patients with Glioblastoma , 2003, Strahlentherapie und Onkologie.

[42]  J. Overgaard,et al.  Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone. , 1995, Acta oncologica.